PL2094684T3 - 1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1 - Google Patents

1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1

Info

Publication number
PL2094684T3
PL2094684T3 PL07871197T PL07871197T PL2094684T3 PL 2094684 T3 PL2094684 T3 PL 2094684T3 PL 07871197 T PL07871197 T PL 07871197T PL 07871197 T PL07871197 T PL 07871197T PL 2094684 T3 PL2094684 T3 PL 2094684T3
Authority
PL
Poland
Prior art keywords
dihydropyrrolidin
benzylamino
diphenyl
ones
receptor modulators
Prior art date
Application number
PL07871197T
Other languages
English (en)
Inventor
David Scott Coffey
Jingdan Hu
Stacy Jo Keding
Joseph Herman Junior Krushinski
John Mehnert Schaus
David Edward Tupper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2094684T3 publication Critical patent/PL2094684T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/382-Pyrrolones
PL07871197T 2006-10-23 2007-10-22 1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1 PL2094684T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
PCT/US2007/082042 WO2008070306A2 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators
EP07871197A EP2094684B1 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin 2-ones as cb1 receptor modulators

Publications (1)

Publication Number Publication Date
PL2094684T3 true PL2094684T3 (pl) 2011-05-31

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07871196T PL2099784T3 (pl) 2006-10-23 2007-10-22 1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1
PL07871197T PL2094684T3 (pl) 2006-10-23 2007-10-22 1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07871196T PL2099784T3 (pl) 2006-10-23 2007-10-22 1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1

Country Status (23)

Country Link
US (2) US8168659B2 (pl)
EP (2) EP2099784B1 (pl)
JP (2) JP5331002B2 (pl)
KR (2) KR101088229B1 (pl)
CN (2) CN101528732B (pl)
AR (1) AR063497A1 (pl)
AT (1) ATE492543T1 (pl)
AU (1) AU2007329808B2 (pl)
BR (1) BRPI0717347A2 (pl)
CA (2) CA2667210C (pl)
CL (1) CL2007003002A1 (pl)
CY (1) CY1111140T1 (pl)
DE (1) DE602007011495D1 (pl)
DK (2) DK2094684T3 (pl)
EA (2) EA015175B1 (pl)
ES (2) ES2398388T3 (pl)
MX (2) MX2009004054A (pl)
PE (1) PE20080926A1 (pl)
PL (2) PL2099784T3 (pl)
PT (2) PT2094684E (pl)
SI (2) SI2094684T1 (pl)
TW (1) TW200825067A (pl)
WO (2) WO2008070305A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
CN102007121B (zh) 2008-04-22 2013-08-14 伊莱利利公司 作为cb-1配体的1,5-二苯基-吡咯烷-2-酮化合物
CN102119029B (zh) * 2008-04-22 2013-03-13 伊莱利利公司 作为cb-1配体的1,5-二苯基-吡咯烷-2-酮化合物
US20110280813A1 (en) * 2008-11-13 2011-11-17 Alice Prince Neuraminidase inhibitors and uses thereof
BR112013000841A2 (pt) * 2010-07-15 2016-06-07 Oleg Lliich Epshtein composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2022132803A1 (en) * 2020-12-14 2022-06-23 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
ES2315851T3 (es) * 2004-02-19 2009-04-01 Solvay Pharmaceuticals B.V. Derivados de imidazolina que tienen actividad antagonista cb1.
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Also Published As

Publication number Publication date
ES2398388T3 (es) 2013-03-15
WO2008070305A3 (en) 2008-08-28
US20090275618A1 (en) 2009-11-05
AU2007329808B2 (en) 2013-11-07
CN101528732B (zh) 2013-04-03
JP2010507589A (ja) 2010-03-11
CN101528732A (zh) 2009-09-09
KR101088229B1 (ko) 2011-11-30
CN101528733A (zh) 2009-09-09
EP2099784B1 (en) 2012-12-12
PE20080926A1 (es) 2008-07-19
KR20090069316A (ko) 2009-06-30
MX2009004054A (es) 2009-04-27
CA2667372C (en) 2013-09-03
CA2667210C (en) 2013-09-24
AU2007329808A1 (en) 2008-06-12
DK2099784T3 (da) 2013-01-14
KR101088236B1 (ko) 2011-11-30
CL2007003002A1 (es) 2008-06-06
KR20090071613A (ko) 2009-07-01
US7998985B2 (en) 2011-08-16
JP5331002B2 (ja) 2013-10-30
EA015175B1 (ru) 2011-06-30
ATE492543T1 (de) 2011-01-15
EA200970404A1 (ru) 2009-10-30
PL2099784T3 (pl) 2013-05-31
WO2008070305A2 (en) 2008-06-12
AR063497A1 (es) 2009-01-28
EP2094684B1 (en) 2010-12-22
WO2008070306A2 (en) 2008-06-12
WO2008070306A3 (en) 2008-07-31
BRPI0717347A2 (pt) 2014-01-14
ES2356025T3 (es) 2011-04-04
PT2094684E (pt) 2011-01-28
SI2094684T1 (sl) 2011-04-29
EP2099784A2 (en) 2009-09-16
EA015745B1 (ru) 2011-10-31
PT2099784E (pt) 2013-01-04
EP2094684A2 (en) 2009-09-02
US20100016375A1 (en) 2010-01-21
DE602007011495D1 (de) 2011-02-03
CA2667210A1 (en) 2008-06-12
DK2094684T3 (da) 2011-03-14
CN101528733B (zh) 2013-10-16
AU2007329807A1 (en) 2008-06-12
JP2010507590A (ja) 2010-03-11
SI2099784T1 (sl) 2013-02-28
EA200970405A1 (ru) 2009-12-30
TW200825067A (en) 2008-06-16
MX2009004053A (es) 2009-04-27
CA2667372A1 (en) 2008-06-12
US8168659B2 (en) 2012-05-01
JP5331001B2 (ja) 2013-10-30
CY1111140T1 (el) 2015-06-11

Similar Documents

Publication Publication Date Title
IL198990A0 (en) Cb1 receptor modulators
GB0623101D0 (en) Secure network architecture
IL201973A0 (en) 3,3-spiroindolinone derivatives
IL225694A0 (en) Compounds 6,5- dihydro-h1-pyridine-2-one
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
PL2099784T3 (pl) 1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1
IL191767A0 (en) Imidazoles as gaba-b receptor modulators
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
GB0701992D0 (en) Grehlin Receptor Modulators
ZA201004828B (en) Cannabinoid receptor modulators
IL188388A0 (en) Pyrazole derivatives as cb1 modulators
EP2097410A4 (en) HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
GB0616467D0 (en) Network tunnelling
GB0622569D0 (en) Cannabinoid receptor modulators
ZA200806237B (en) Cannibinoid receptor modulators
AU2008207290A8 (en) Stirrup
DE602006020489D1 (de) Cb1-rezeptormodulatoren
IL194972A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-
GB0811212D0 (en) CB1 Receptor Modulators
ZA200904663B (en) CB1 receptor modulators
GB0719111D0 (en) T.m.2
GB0724096D0 (en) Cannabinoid receptor modulators
GB0623399D0 (en) Receptor
GB0604684D0 (en) Receptor
GB0623853D0 (en) Receptor